The contribution of six polymorphisms to cardiovascular risk in a Dutch high-risk primary care population: The HIPPOCRATES project

Journal of Human Hypertension

Volumn 23, Issue 10, 2009, Pages 659-667

  Plat, A W ^a,b   Stoffers, H E J H ^a   Klungel, O H ^c   van Schayck, C P ^a   de Leeuw, P W ^b   Soomers, F L ^a   Schiffers, P M ^b   Kester, A D M ^a   Kroon, A A ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ALPHA ADDUCIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; ASPARTIC ACID; CYSTEINE; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; G PROTEIN BETA 3 SUBUNIT; GLUTAMIC ACID; GLYCINE; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; METHIONINE; THREONINE; TRYPTOPHAN; UNCLASSIFIED DRUG;

AGED; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; POPULATION BASED CASE CONTROL STUDY; PREDICTION; PRIMARY MEDICAL CARE; QUANTITATIVE ANALYSIS; RISK ASSESSMENT;

AGED; ANGIOTENSINS; CALMODULIN-BINDING PROTEINS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NETHERLANDS; NITRIC OXIDE SYNTHASE TYPE III; ODDS RATIO; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; PRIMARY HEALTH CARE; RECEPTOR, ANGIOTENSIN, TYPE 1; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE;

EID: 70349449699     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.6     Document Type: Article

References (38)

1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364: 937-952.
2. Chen Y, Rollins J, Paigen B, Wang X. Genetic and genomic insights into the molecular basis of atherosclerosis. Cell Metab 2007; 6: 164-179.
3. Jeunemaitre X. Genetics of the human renin angiotensin system. J Mol Med 2008; 86: 637-641.
4. Hegele RA. SNP judgments and freedom of association. Arterioscler Thromb Vasc Biol 2002; 22: 1058-1061.
5. Plat AW, Te Wierik MJ, Kroon AA, Schouten HJ, van den Akker M, van Schayck CP et al. Regional differences in cardiovascular risk factor profile cannot fully explain differences in cardiovascular morbidity in the Netherlands: A comparison of two urban areas. Neth J Med 2005; 63: 309-315.
6. Henskens LH, Spiering W, Stoffers HE, Soomers FL, Vlietinck RF, de Leeuw PW et al. Effects of ACE I/D and AT1R-A1166C polymorphisms on blood pressure in a healthy normotensive primary care population: First results of the Hippocrates study. J Hypertens 2003; 21: 81-86.
7. van Onna M, Kroon AA, Houben AJ, Koster D, Zeegers MP, Henskens LH et al. Genetic risk of atherosclerotic renal artery disease: The candidate gene approach in a renal angiography cohort. Hypertension 2004; 44: 448-453.
8. Metsemakers JF, Knottnerus JA, van Schendel GJ, Kocken RJ, Limonard CB. Unlocking patients' records in general practice for research, medical education and quality assurance: The Registration Network Family Practices. Int J Biomed Comput 1996; 42: 43-50.
9. Landwehr JSTM, Akker Mvd, Metsemakers JFM, Buntinx F. Comorbidity of chronic cardiovascular disorders. A cross-sectional analysis in a large general practice population in the Netherlands. Archiv Public Health 2000; 58: 213-231.
10. Classification Committee of the WONCA: ICHPPC-2-Defined International Classification of Health Problems in Primary Care, 3rd edn. Oxford University Press: Oxford, 1983.
11. Lamberts H, Wood M (eds). ICPC: International Classification of Primary Care. Oxford University Press: Oxford, 1987.
12. Cifkova R, Erdine S, Fagard R, Farsang C, Heagerty AM, Kiowski W et al. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003; 21: 1779-1786.
13. Knaapen AM, Ketelslegers HB, Gottschalk RW, Janssen RG, Paulussen AD, Smeets HJ et al. Simultaneous genotyping of nine polymorphisms in xenobiotic-metabolizing enzymes by multiplex PCR amplification and single base extension. Clin Chem 2004; 50: 1664-1668.
14. Villard E, Tiret L, Visvikis S, Rakotovao R, Cambien F, Soubrier F. Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet 1996; 58: 1268-1278.
15. Keavney B, McKenzie CA, Connell JM, Julier C, Ratcliffe PJ, Sobel E et al. Measured haplotype analysis of the angiotensin-I converting enzyme gene. Hum Mol Genet 1998; 7: 1745-1751.
16. Veldman BA, Spiering W, Doevendans PA, Vervoort G, Kroon AA, de Leeuw PW et al. The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens 2002; 20: 2023-2027.
17. Visvikis S, Sass C, Pallaud C, Grow MA, Zannad F, Siest G et al. Familial studies on the genetics of cardiovascular diseases: The Stanislas cohort. Clin Chem Lab Med 2000; 38: 827-832.
18. Tobin MD, Braund PS, Burton PR, Thompson JR, Steeds R, Channer K et al. Genotypes and haplotypes predisposing to myocardial infarction: A multilocus case-control study. Eur Heart J 2004; 25: 459-467.
19. Herings R. PHARMO: A Record Linkage System for Postmarketing Surveillance of Prescription Drugs in The Netherlands. Utrecht University: Utrecht, 1993.
20. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen. J Hypertens 2004; 22: 1831-1837.
21. Despres JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E et al. Abdominal obesity and the metabolic syndrome: Contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008; 28: 1039-1049.
22. Ryan DH. The relationship among risk factor clustering, abdominal obesity, and residual risk for cardiovascular events. Rev Cardiovasc Med 2007; 8: 9-16.
23. Hosmer DW, Lemeshow S. Applied Logistic Regression, 2nd edn. Wiley: New York, 2000.
24. Keavney B, McKenzie C, Parish S, Palmer A, Clark S, Youngman L et al Large-scale test of hypothesised associations between the angiotensin-convertingenzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators. Lancet 2000; 355: 434-442.
25. Sethi AA, Tybjaerg-Hansen A, Gronholdt ML, Steffensen R, Schnohr P, Nordestgaard BG. Angiotensinogen mutations and risk for ischemic heart disease, myocardial infarction, and ischemic cerebrovascular disease. Six case-control studies from the Copenhagen City Heart Study. Ann Intern Med 2001; 134: 941-954.
26. Renner W, Hoffmann MM, Grunbacher G, Winkelmann BR, Boehm BO, Marz W. G-protein beta3 subunit (GNB3) gene polymorphisms and cardiovascular disease: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Atherosclerosis 2007; 192: 108-112.
27. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A et al. Molecular basis of human hypertension: Role of angiotensinogen. Cell 1992; 71: 169-180.
28. Winkelmann BR, Russ AP, Nauck M, Klein B, Bohm BO, Maier V et al. Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease. Am Heart J 1999; 137: 698-705.
29. Xu MQ, Ye Z, Hu FB, He L. Quantitative assessment of the effect of angiotensinogen gene polymorphisms on the risk of coronary heart disease. Circulation 2007; 116: 1356-1366.
30. Fernandez-Arcas N, Dieguez-Lucena JL, Munoz-Moran E, Ruiz-Galdon M, Espinosa-Caliani S, Aranda-Lara P et al. Both alleles of the M235T polymorphism of the angiotensinogen gene can be a risk factor for myocardial infarction. Clin Genet 2001; 60: 52-57.
31. Lizanecz E, Pasztor ET, Mohacsi A, Papp Z, Edes I, Toth A. Mistyping of angiotensinogen M235T alleles. Hypertens Res 2006; 29: 197-201.
32. Bianchi G, Ferrari P, Staessen JA. Adducin polymorphism: Detection and impact on hypertension and related disorders. Hypertension 2005; 45: 331-340.
33. Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN, Reiner AP et al Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002; 287: 1680-1689.
34. Baudin B. Polymorphism in angiotensin II receptor genes and hypertension. Exp Physiol 2005; 90: 277-282.
35. Diverse Populations Collaborative Group. Prediction of mortality from coronary heart disease among diverse populations: Is there a common predictive function? Heart 2002; 88: 222-228.
36. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003; 24: 987-1003.
37. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
38. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus small studies: An empirical assessment. Lancet 2003; 361: 567-571.